ReviewClinical reviews in allergy & immunology2015
Treatment of Sarcoidosis.
Review in Clinical reviews in allergy & immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Isolated cardiac sarcoidosis: A systematic review.The Journal of international medical research · 2025Pooled it
- Sarcoidosis as an Autoimmune Disease.Frontiers in immunology · 2019Pooled it
- [Diagnosis and treatment of sarcoidosis. Current standards].Der Internist · 2015Guideline
- Therapeutic Applications of Immunobiologics in Autoimmune and Inflammatory Diseases.Pharmaceutics · 2026Review
- Exploratory laparotomy and drainage of a left pelvic abscess: a case report.Journal of surgical case reports · 2026Article
- The textures of sarcoidosis: quantifying lung disease through variograms.Physics in medicine and biology · 2025Article
- Microbiota and antibiotic exposure in sarcoidosis.Frontiers in immunology · 2025Review
- Rheumatologic Perspectives on Sarcoidosis: Predicting Sarcoidosis-Associated Arthritis Through Comprehensive Clinical and Laboratory Assessment.Journal of clinical medicine · 2024Article
- The textures of sarcoidosis: quantifying lung disease through variograms.medRxiv : the preprint server for health sciences · 2024Article
- Deep lymph node enlargement and renal failure caused by hypercalcemia‑associated sarcoidosis: A case report.Experimental and therapeutic medicine · 2024Article
- High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism Abnormalities.Diagnostics (Basel, Switzerland) · 2024Review
- Neurosarcoidosis.Journal of neurology · 2024Article
- Transcatheter arterial chemoembolization of apatinib and camrelizumab (SHR1210) against liver metastasis from hepatic neuroendocrine tumor: a case report.Frontiers in oncology · 2024Article
- Diagnosis of systemic sarcoidosis in a patient with bilateral granulomatous pan-uveitis: a case report.Annals of medicine and surgery (2012) · 2024Article
- A single-center rheumatology experience of sarcoidosis: observations from 70 patients.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity.Clinical reviews in allergy & immunology · 2023Review
- [Sarcoidosis].Zeitschrift fur Rheumatologie · 2023Article
- Sarcoidosis and Autoimmune Inflammatory Syndrome Induced by Adjuvants.Life (Basel, Switzerland) · 2023Review
- Perspective of sarcoidosis in terms of rheumatology: a single-center rheumatology clinic experience.Rheumatology international · 2022Article
- Detection of Anti-Vimentin Antibodies in Patients with Sarcoidosis.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In general, sarcoidosis treatment should be offered to palliate symptoms and improve quality of life or to prevent end-organ disease. Symptoms include pulmonary as well as extra-pulmonary manifestations of the disease. The assessment of response to disease includes functional studies such as the forced vital capacity. Radiologic imaging such as chest x-ray has also been used to assess response, although standardized measures have rarely been tested. There are sufficient clinical trials to make specific recommendations regarding treatment of symptomatic pulmonary disease. Initial therapy is usually prednisone or a similar glucocorticoid. However, there are several features of this treatment which are unknown. This includes the initial dose, timing of reduction of dose, and when to discontinue treatment. Since many patients are intolerant of prednisone, steroid-sparing alternatives have been studied. Methotrexate is the most widely used anti-metabolite, but azathioprine, leflunomide, and mycophenolate have also been reported as helpful. The biologic agents, especially monoclonal anti-tumor necrosis factor (anti-TNF) antibodies, have proved effective in patients who have failed other treatments. Infliximab, the most widely studied anti-TNF antibody, has proved effective for a range of refractory sarcoidosis. However, there remain questions regarding dose and duration of therapy. For the clinician, the many treatment options allow for a specific treatment regimen for each patient which minimizes risk while enhancing benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.